CD274 and neoplasm: Results from an interim analysis of the KEYNOTE-051 trial indicated that Pembrolizumab exhibited anti-tumor activity in pediatric patients with advanced melanoma and PD-L1-positive, advanced, relapsed, or refractory solid tumor or lymphoma (5).